Skip to content
10-K

Annual Report

ATYR PHARMA, INC. ATYR

0000950170-25-038888

← back to feed
Filed
Mar 13, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Mar 7, 2025 88.86M sh
Stockholders Equity FY 2024 · Dec 31, 2023 $90.66M
Current Liabilities FY 2024 · Dec 31, 2023 $16.42M
Current Assets FY 2024 · Dec 31, 2023 $102.99M
Total Assets FY 2024 · Dec 31, 2023 $120.65M
Shares Diluted FY 2024 · Dec 31, 2022 28.42M sh
Capex FY 2024 · Dec 31, 2022 $1.64M
Operating Cash Flow FY 2024 · Dec 31, 2022 −$41.89M
Cash And Equivalents FY 2024 · Dec 31, 2022 $9.98M
Eps Diluted FY 2024 · Dec 31, 2022 −$1.60
Eps Basic FY 2024 · Dec 31, 2022 −$1.60
Sga Expense FY 2024 · Dec 31, 2022 $13.98M
Rd Expense FY 2024 · Dec 31, 2022 $42.81M
Net Income FY 2024 · Dec 31, 2022 −$45.34M
Operating Income FY 2024 · Dec 31, 2022 −$46.4M
Revenue FY 2024 · Dec 31, 2022 $10.39M